Amgen, Sandoz Seek Rehearing On Biosimilar Court Case
This article was originally published in SRA
Executive Summary
Amgen and Sandoz have both filed petitions asking the US Court of Appeals for the Federal Circuit to rehear a panel ruling interpreting the provisions of the biosimilars statute. Amgen argues against the finding that the information exchange process in the law is optional, while Sandoz objects to the panel’s decision that biosimilar sponsors must wait until Food and Drug Administration approval to provide notice of commercial launch1,2.
You may also be interested in...
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.
Off-Label Communication: Industry Opposes Exclusion Of Phase II Data From US FDA’s Guidance
Revised draft guidance about scientific information on unapproved uses (SIUU) of medical products is “impermissibly paternalistic and overly restrictive of scientific speech,” MIWG says.